We describe a single centre experience of eight consecutive patients with relapsed or refractory Ph + ALL treated with the FLAG/idarubicin regimen followed by BMT or PBSCT. Following FLAG/idarubicin, one achieved a partial response and seven CR. All patients subsequently received allogeneic transplants: one sibling BMT, three matched unrelated (MUD) BMT and four sibling PBSCT. Two patients received second transplants with PBSC from their original BM donors following FLA/Ida with no further conditioning. Three patients are alive in CR 9, 24 and 32 months after transplant. Seven of eight patients had a cytogenetic response following FLAG/Ida induction and one of seven became bcr-abl negative. All eight patients had a complete cytogenetic response following transplant. Four of five assessable patients became p190 bcr-abl negative after transplant; three of these subsequently relapsed. Both patients with the p210 bcr-abl transcript remained bcrabl positive in CR after transplant. FLAG/Ida was well tolerated and appears to be effective in inducing remission in relapsed Ph + ALL. The use of FDR-containing chemotherapy without further conditioning prior to PBSCT deserves further study in heavily pretreated patients and, in patients with relapsed ALL following BMT, may be a safer option than DLI (donor lymphocyte infusion) by avoiding the associated risk of aplasia. Keywords: fludarabine; FLAG; acute lymphoblastic leukaemia; Philadelphia chromosome; bcr-abl; peripheral blood stem cell transplantation The Ph chromosome, t(9;22)(q34;q11), is detected in up to 25% of adults and in 2-6% of children with ALL and the bcr-abl transcript is detectable by PCR in up to 32% of adults with ALL.
median CR duration of 7 months and 13% 3-year diseasefree survival (DFS) probability in adults. 1, 2, 4 BMT from a sibling donor is a more effective treatment with 2-year DFS probabilities of 38 and 46% for patients in 1st CR and 41 and 28% for patients beyond 1st CR in the IBMTR series 5 and the series reported by Chao et al. 6 Radich et al 7 reported 30 patients who received BMT in CR or relapse, of whom nine were disease-free beyond 2 years. Casper et al 8 reported 68% DFS at 13 months in 14 paediatric patients who received BMT in CR.
The results of chemotherapy in patients with relapsed acute leukaemia after BMT are poor especially in those who relapse early. 9 Second BMT is associated with a high mortality and morbidity especially when performed within 1 year of the initial transplant with only 10% long-term survivors in the IBMTR series. [10] [11] [12] The role of DLI as adoptive immunotherapy for relapsed CML after BMT has been established in recent years. [13] [14] [15] [16] [17] [18] [19] This approach has also been used in relapsed AML after BMT but has been less successful in ALL. [19] [20] [21] [22] [23] However, there are reports of success in ALL when DLI has been combined with cytokines or preceded by chemotherapy. 24, 25 Although the feasibility of allogeneic PBSCT as a primary transplant is established, [26] [27] [28] its use as second transplant has so far been described only in individual cases. [29] [30] [31] [32] [33] [34] There is relatively little data available on the pattern of bcr-abl detection by PCR in Ph + ALL following treatment. In the largest series reported, 7 the risk of relapse was significantly associated with p190 but not p210 bcr-abl positivity after BMT.
The FLAG or FLAG-idarubicin regimens, which combine fludarabine (FDR), high-dose ara-C and G-CSF with or without idarubicin (Ida), have recently been used with good responses in poor risk AML and myelodysplasia and refractory or relapsed ALL. [35] [36] [37] [38] The rationale of these regimens is that the agents appear to be synergistic. 39, 40 FDR triphosphate, the active metabolite of FDR, inhibits ribonucleotide reductase with a subsequent accumulation of intracellular ara-CTP. A positive correlation has been found between intracellular ara-CTP and remission rates. 41 G-CSF prior to FDR increases the fraction of cells in cycle when they are most vulnerable to ara-C. 40 Ida may not be as susceptible to multidrug resistance as other anthracyclines as it does not induce P-glycoprotein expression in leukaemic cell lines. ALL, reinduced with FLAG/Ida followed by allogeneic transplantation, and describe the results of cytogenetic and molecular monitoring.
Patients, donors and methods

Patients
Eight consecutive patients treated for relapsed or refractory Ph + ALL between August 1995 and July 1997 at a single centre are described. Patient details are shown in Table 1 . Patient 2 was treated with FLAG/Ida at the time of cytogenetic relapse 5 months after remission induction with the MRC UKALL 12 schedule. Patient 7 had a BMT in 2nd CR, a testicular relapse 2 years later and was treated with FLAG/Ida at the time of CNS relapse a year later. The remaining six patients had morphological BM relapse at the time of treatment with FLAG/Ida. Patients 1 and 5 relapsed on maintenance treatment at 11 and 23 months following remission induction. Patient 5, a 20-year-old male, refused a matched sibling BMT in 1st CR. Patient 6 relapsed 10 weeks following BMT; he received DLI (1 ϫ 10 7 CD3 cells/kg) in cytogenetic relapse but progressed to develop frank morphological relapse when he was treated with FLAG/Ida. Patient 3 had been refractory to standard induction and subsequent combination chemotherapy over a period of 5 months following diagnosis. Patient 4 was treated with four courses of ara-C and daunorubicin because of an initial diagnosis of AML and was treated with FLAG/Ida at the time of relapse 3 months later. Patient 8 presented with a biphenotypic leukaemia and was treated with FLAG/Ida following a partial response to ADE10 with weekly VCR.
In addition to the Ph chromosome, seven of eight patients (patients 1-7) had additional cytogenetic abnormalities associated with adverse prognostic significance. Cytogenetic results on two patients were first available at the time of refractory disease or relapse: patient 3 had complex cytogenetic abnormalities including monosomy 7 and patient 4 had del(11q23). Five patients developed additional cytogenetic abnormalities at relapse: patient 1, an additional Ph chromosome and monosomy 7; patient 2, 6q−; patient 5, 7q−; patient 6, additional clonal abnormalities and additional Ph chromosomes; patient 7, independent com- plex clones thought to have evolved from the original Ph + clone.
Reinduction chemotherapy
Seven patients were reinduced with FLAG Ida (fludarabine 30 mg/m 2 , ara-C 2 g/m 2 days 1-5, G-CSF 300 g/m 2 day Ϫ1 to neutrophil recovery, Ida 8 mg/m 2 days 1-3) and patient 2 with FLAG. Four patients had a second course of FDR ara-C (patients 3, 6 and 8) or FDR ara-C Ida (patient 7) according to the same schedule. Patients 3 and 7 had CNS disease and received additional local chemotherapy.
Donors
Patients 1, 2 and 8 received bone marrow from matched unrelated donors: the donor for patient 1 was fully HLAmatched; patient 2 received BMT from a DRB2-mismatched donor with a CTLp of one in 10 000; patient 8 received BMT from a C-mismatched donor. The donors for the other patients were fully HLA-matched siblings. Patient 3 received BM and patients 4, 5, 6 and 7, PBSC allografts. Patients 1, 3 and 8 received sex-mismatched BMTs and the remaining patients, sex-matched transplants. Informed consent was obtained using institutional guidelines.
Mobilisation, collection and transplantation of PBSC
PBSC donors were given 10 g/kg G-CSF as a single daily subcutaneous injection for 4 or 5 days, with day 5 timed to coincide with day 0 of the allograft. Leukapheresis was commenced once the number of peripheral blood CD34 cells exceeded 20/l. 43 Donor venous access was obtained by bilateral antecubital venepuncture. Leukapheresis was performed using a continuous flow blood cell separator (Cobe Laboratories, Lakewood, CO, USA), processing 15 l of blood on each occasion. The donors tolerated G-CSF and leukapheresis without complications. The results of the leukaphereses are shown in Table 2 . The leukapheresis products were administered fresh in all cases. In the cases of patients 6 and 7, the leukapheresis products were aliquoted and an aliquot containing 2 ϫ 10 6 /kg CD34 cells was administered. The leukapheresis product for patient 4 was partially T cell-depleted by treatment of half of the product FLAG-idarubicin and allogeneic transplantation for Ph + ALL M Deane et al 1139 Table 2 Characteristics of G-CSF-mobilised PBSC with Campath IG 0.1 g/10 6 MNC (P Jacobs, personal communication).
Bone marrow transplantation
Patient 1 received a MUD BMT at another institution; details were unavailable. The unrelated bone marrow for patients 2 and 8 was fully T cell-depleted using Campath IgM (0.24 and 0.01 ϫ 10 6 CD3 cells/kg infused, respectively). Patient 3 received unmanipulated bone marrow.
Conditioning and prophylaxis
The details for patient 1 were not available. Patients 2, 3, 4 and 5 received TBI 750 cGy as a single fraction and cyclophosphamide 120 mg/kg. Patients 2 and 8, who were MUD BMT recipients, in addition received TLI 900 cGy in six fractions and a 5-day course of Campath 1G. Patients 3, 6 and 7 were transplanted at the time of nadir counts, day 10, following a second course of FDR ara-C (patient 6) or FDR ara-C Ida (patient 7). Patients 6 and 7 received no additional conditioning. All patients were given intravenous CY from day Ϫ1 and patient 8 short MTX (see Table 3 ).
Documentation of engraftment and remission
Haemopoietic recovery was defined by recovery of the neutrophil count to Ͼ0.5x10 9 /l and an unsupported platelet count of Ͼ20x10 9 /l. Reverse transcriptase PCR was used to detect bcr-abl transcripts as previously described. 44 At diagnosis, six of the eight patients were p190 bcr-abl positive and two patients (patients 4 and 8), p210 bcr-abl-positive. Chimeric studies were performed in the cases of patients 6 and 7 using pre-transplant DNA extracted from donor and recipient. The DNA profile was compared using a panel of short tandem repeat markers as previously described. 45 Two informative markers were used in each case.
Results
Response to reinduction chemotherapy
Five (patients 3, 4, 5, 6 and 8) of the six patients with morphological bone marrow disease achieved morphological CR following a single course of FLAG/Ida. Patient 1 had a partial response with a reduction in bone marrow blasts from 90 to 50%.
Patient 7 had CNS disease associated with complex abnormal cytogenetic clones in the BM, thought to have evolved from the original Ph + clone, and responded to local and systemic treatment. The patient had previously had a BMT: chimaeric studies before and 6 weeks after FLAGIda reinduction showed a reduction in the proportion of BM recipient haemopoiesis from 30 to Ͻ10% with a parallel reduction in the proportion of the abnormal cytogenetic clones (data not shown).
The results of the cytogenetic and PCR responses to reinduction chemotherapy are illustrated in Table 1 and Figure  1 . Seven of eight patients achieved a cytogenetic response and one of seven patients tested, patient 6, became bcrabl-negative. FLAG/Ida was generally well tolerated in all patients, the main side-effects being a self-limiting skin rash and abnormal liver function tests. There were no toxic deaths.
Results of PBSCT and BMT
The outcome and details of haemopoietic recovery are summarised in Table 3 . Six patients had grade I or II GVHD of the skin and/or gut which responded to treatment. negative bcr-abl PCR assays 11 weeks and 10 months prior to bone marrow relapse. Chimaeric studies on patient 6 at the time of the negative bcr-abl assay 11 weeks post-transplant and 10 months prior to relapse showed complete donor chimaerism (data not shown). Patient 3 had a negative bcr-abl assay 4 weeks prior to a local orbital relapse and had a bone marrow relapse 4 months later. Patient 8 remained p210 bcr-abl-positive at 3 months and is in CR 5 months after BMT. Patient 4 remained p210 bcr-abl-positive, Ph-negative at 7 months and died of infection 12 months post-transplant. Patient 6 had a second CR of 13 months after PBSCT having relapsed 10 weeks following initial BMT in 1st CR. Patient 7 who had a CNS relapse has been in CR for 28 months after a second transplant with a preceding CR of 12 months; cytogenetic studies which had previously shown complex abnormal clones have been persistently normal from 3 weeks after PBSCT.
Discussion
We chose to use the FLAG/Ida regimen in this series of high risk and heavily pre-treated patients because of its reported efficacy and our own experience in its use in treatment of refractory leukaemia, as well as an acceptable toxicity profile. The main complication of FDR therapy is prolonged immunosuppression which becomes irrelevant after allogeneic stem cell transplantation. Seven of eight patients achieved CR, including two with previously refractory disease, and one, a partial response, following a single course of FLAG/Ida. Seven patients had a cytogenetic response following FLAG/Ida reinduction and one became bcr-abl negative. Gehly et al 46 reported Ph negativity in three of eight patients in CR following chemotherapy all of whom remained bcr-abl-positive. Mitterkauer et al 47 reported transient bcr-abl negativity in two patients following chemotherapy or BMT.
Although the number of patients in this series is small, the 2-year DFS of 47.6% compares well with the reported 2-year DFS of 41 and 28% in patients transplanted beyond 1st CR, 5, 6 particularly as ours is a high risk group of patients on the basis of cytogenetic abnormalities.
In our series, bcr-abl negativity was not predictive of relapse risk. Of four patients p190 bcr-abl negative at 3- 48 reported PCR negativity in nine of 15 patients who received auto-or allo-BMT, seven of whom remained PCR-negative and disease-free at follow-up of 15-64 months. Radich et al 7 reported PCR negativity in 14 of 31 patients after BMT. In this study, the risk of relapse correlated with p190 but not p210 bcr-abl positivity.
Two of the patients in this series relapsed following BMT and had second transplants with PBSC from the same donors, one 4 months and the second more than 3 years after BMT. One relapsed 13 months following the second transplant; the second patient remains in CR at 28 months. Both patients engrafted in the expected time-scale, with restoration of complete donor chimaerism demonstrated in both. Neither patient suffered from significant procedure related toxicity, although both patients have developed chronic GVHD, neither having had GVHD after their initial BMTs. The results of reinduction chemotherapy for relapsed acute leukaemia after BMT are very poor with 7% CR in patients given chemotherapy for ALL relapsing within 100 days of transplant compared to 65% CR for relapse beyond 1 year in the series reported by Mortimer et al. 9 Similarly the results of second BMT are very poor in patients with early relapse of acute leukaemia. Sanders et al 11 reported one survivor among 15 patients transplanted within 2 years of the initial transplant and six survivors among 11 patients transplanted more than 2 years after initial BMT. Given the poor prognosis in patients with early relapse after BMT, the use of DLI has seemed an attractive approach. However, the EBMT data on use of DLI for relapsed ALL following BMT shows no CR in 12 patients who either failed to respond to chemotherapy or were treated with DLI alone, whereas three of nine patients treated with chemotherapy prior to DLI remained in CR at 70-298 days. 19 In the case of the patient in this series treated with DLI, DLI alone was not effective when given in early relapse, whereas PBSCT following chemotherapy induced complete donor chimaerism and a CR which lasted for 13 months. Marrow aplasia can occur in more than 50% of patients given DLI for relapsed disease without prior chemotherapy. 49 In the context of the rapid disease kinetics of relapsed ALL, there are clear advantages to the use of chemotherapy followed by PBSCT rather than DLI alone, in that this approach avoids the risks of aplasia and provides rapid haemopoietic reconstitution and restoration of chimaerism.
Three patients were transplanted at the time of nadir counts following FDR ara-C/Ida. Two of these patients had previous BMTs and received no further conditioning treatment. The use of FDR, which induces T cell depletion, 50, 51 avoided the toxicity of standard CY and TBI regimens in the patients receiving second transplants. Giralt et al 52 have recently described a similar approach with use of non-myeloablative purine analogue-containing chemotherapy prior to allogeneic PBSCT or BMT in patients who were not considered fit for standard conditioning regimens.
The dose of T cells in T cell-depleted BM transplants correlates with risk of GVHD 53 but data, presently contradictory, does not so far indicate a correlation of GVHD with the dose of T cells in PBSC allografts perhaps because a critical threshold has been exceeded. Given that two of our patients were receiving second transplants, we used PBSC products containing 2 ϫ 10 6 CD34 cells/kg and Ͻ2 ϫ 10 8 CD3 cells/kg, in the absence of definitive data on whether the risk of GVHD correlates with the dose of T cells in PBSCT.
Although the follow-up of some of the surviving patients in this series is relatively limited, the results illustrate that FLAG/Ida regimens can be useful in providing rapid disease control in patients with relapsed or refractory Ph + ALL prior to allogeneic transplantation. The use of these regimens in heavily pre-treated patients without further conditioning prior to transplantation avoids the toxicity of conventional conditioning regimens. Further studies are needed to define the optimum cellular composition of second transplants using PBSC which provide engraftment with minimal risk of GVHD. As in other studies of Ph + ALL, treatment of this disorder remains inadequate. However, we would suggest that the use of PBSCT following FDR/ara-C induction and conditioning deserves further study in ALL relapsed after BMT in the context of a multi-centre study and may be a safer and more effective option than DLI.
